Impulsive and compulsive behaviors have become increasingly associated with Parkinson disease (PD) and treatment. Recently, the International Parkinson’s and Movement Disorder Society commissioned a task force to assess currently available screening tools and rating scales in order to make recommendations regarding their utility, as well as to inform future directions in scale development and validation.
Impulsive and compulsive behaviors (ICBs) have become increasingly associated with Parkinson disease (PD) and treatment. Recently, the International Parkinson’s and Movement Disorder Society commissioned a task force to assess currently available screening tools and rating scales in order to make recommendations regarding their utility, as well as to inform future directions in scale development and validation.
Members of the task force conducted a systematic review on available screening tools and scales used in PD studies to detect a range of impulse control disorders (ICDs), including compulsive medication use, pathological gambling, hypersexuality, binge eating, and reckless driving, among others.
The group identified 50 scales used to measure the severity of ICDs in studies of patients with PD. Study investigators assessed each scale for descriptive and clinometric properties, availability content, use, acceptability, and overall impression in patients with PD. The group recommended a scale if it had been applied to PD populations, contained data on the use of the scale in more than 1 cohort, and if the scale was determined as adequate for either screening purposes, assessing symptom severity, or measuring responsiveness to change.
The group reached a few recommendations on which scale to use:
The study authors suggest that early identification of ICDs can help guide treatment decisions in patients with PD, as the presence of multiple ICDs in this population may be associated with poorer quality of life, depression, or treatment resistance. Going forward, the researchers recommend that “further testing of established scales against gold standard diagnostic criteria is urgently required for all other individual ICBs in PD,” wrote the authors.
Reference
Evans A, Okai D, Weintraub D, et al. Members of the International Parkinson and Movement Disorder Society (IPMDS) rating scales review committee. Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: critique and recommendations. Mov Disord. 2019;34(6):791-798.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More